Latest Insights - page 74 | BiopharmaTrend

AI Breaches the Barrier Towards Better CNS Drug Discovery

Bristol Myers Squibb Acquires RayzeBio in a Strategic Move to Expand Radiopharmaceutical Capabilities

In a significant development in the pharmaceutical industry, Bristol Myers Squibb (BMS) has announced the acquisition of RayzeBio, a company specializing in radiopharmaceuticals. This acquisition, valued at $4.1 billion, is …

Continue ›››

The Rising Popularity of Antibody-Drug Conjugates, with Challenges

In the current climate of global economic uncertainty, one area of pharmaceutical development is bucking the trend with a significant surge in activity: the field of antibody-drug conjugates (ADCs). This …

Continue ›››

C4 Therapeutics and Merck Collaborate on Innovative Cancer Treatment

In a recent move in the biotechnology sector, C4 Therapeutics, Inc. (C4T) has announced a collaboration with pharmaceutical giant Merck (MRK). This partnership is centered on the development of degrader-antibody …

Continue ›››

LegoChem Biosciences Strikes Licensing Deal with Janssen for ADC Development

In a new development in the field of cancer treatment, LegoChem Biosciences, Inc., a South Korean biopharmaceutical firm, has announced a major licensing agreement with Janssen Biotech, Inc., a subsidiary …

Continue ›››

Addressing Inequity in Medical Research: The Need to Expand Genomic Databases

Precision medicine is fast developing, with genomics being a particularly promising field. As genomic medicine advances, we get steadily closer to being able to identify the root causes of diseases, develop …

Continue ›››

Unnatural Products Secures $32M to Advance Drug Development with AI-Enhanced Macrocycles

Santa Cruz-based biotech company, Unnatural Products, Inc. (UNP), has recently secured a significant investment of $32 million in its Series A funding round. This round was led by Merck Global …

Continue ›››

SiSaf Advances in Alopecia Treatment with Phase II Trial of Bio-Courier® Technology

In a new development in the field of dermatological therapeutics, SiSaf Ltd, a biopharmaceutical company based in Guildford, UK, has reached a pivotal stage for its novel treatment for alopecia …

Continue ›››

Vandria Gains Momentum with $20.6M Funding to Propel Novel CNS and Mitochondrial Therapies

Vandria SA, a Swiss biotechnology firm specializing in mitochondrial therapeutics, recently announced a significant milestone in its journey. The company has secured $20.6 million (CHF18 million) in Series A financing, …

Continue ›››

ACSR Partners with Proscia to Accelerate Global HIV Cancer Research Through Advanced Digital Pathology Platform

In a recent development for the scientific community, the AIDS and Cancer Specimen Resource (ACSR) has enhanced its ability to provide swift access to valuable pathology data for researchers worldwide. …

Continue ›››

ArtiDock from Receptor.AI: Next-generation AI Docking That Beats DiffDock and AlphaFold-latest

Insilico Medicine’s Generative AI Patent Provides Advantage in AI Drug Discovery Race

Companies are increasingly turning to generative artificial intelligence (AI) to develop new therapeutics, giving biotech companies with patents on these technologies a distinct advantage in the tech-enabled pharmaceutical future. One …

Continue ›››